MIRIKIZUMAB IS EQUALLY EFFECTIVE IN USTEKINUMAB-EXPOSED AND USTEKINUMAB-NAÏVE PATIENTS WITH UC: A MULTICENTRE REAL-WORLD COHORT
Clicks: 1
ID: 317895
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #9 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Mirikizumab, a selective IL-23p19 monoclonal antibody, has demonstrated efficacy in moderate-to-severe ulcerative colitis (UC) although real-world data are limited. In addition, registrational trials excluded patients previously treated with ustekinumab, which targets the IL-12/23 p40 subunit. We aimed to evaluate the real-world effectiveness and safety of mirikizumab in a multicentre UK cohort of patients with UC, including those with prior ustekinumab exposure. Methods A retrospective observational study was conducted across three tertiary UK centres. Adults with confirmed UC who received mirikizumab and had ≥12 weeks of follow-up were included. Data on demographics, disease activity (SCCAI, UCEIS), biomarkers (CRP, faecal calprotectin), and treatment persistence were analysed at 3 and 6 months. Outcomes were compared between ustekinumab-exposed and -naïve patients. Results Among 100 patients (36 ustekinumab-exposed), treatment persistence at 3 months was 72% with no significant difference between groups. SCCAI scores decreased from 5.8 to 3.3 at 3 months (p < 0.00001), and faecal calprotectin decreased from 1094 µg/g to 586 µg/g (p = 0.006). UCEIS scores (n = 36) improved significantly post-induction (mean 4.4 to 2.7, p < 0.000001). Multivariable logistic regression did not reveal any factors associated with treatment persistence, including prior ustekinumab exposure. Adverse events were infrequent and mild. Conclusion Mirikizumab is effective and well tolerated in a real-world UC population, including patients with prior ustekinumab exposure. These findings support the use of IL-23p19 inhibition regardless of previous IL-12/23 blockade.
| Reference Key |
openalex_W7165394877
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mohmmed Tauseef Sharip, Dharmaraj Durai, E Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark Samaan, Tim Raine, Peter M Irving |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag065
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.